Clinical trials: Vivax Malaria
MALARIA, FEVER
Evaluation of Reproducibility of a Sporozoite Challenge Model for Plasmodium Vivax in Human Volunteers
The study is a randomized open label clinical trial to verify the reproducibility of a sporozoite challenge model for Plasmodium vivax in humans.
- Conditions
- MALARIA, FEVER, Sweating Fever, Chills
- Trial name
- NCT00367380
- Testing
- 413ABM, 414WRR, 418JAL
- Where
- Colombia
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Malaria Vaccine and Drug Development Center
Malaria, Vivax
Safety and Immunogenicity of Pvs25-IMX313/Matrix-M1 Vaccine
This is an open-label, single-centre, non-randomised, first-in-human Phase Ia study to assess the safety and immunogenicity of the Pvs25-IMX313 vaccine, administered in Matrix-M1 adjuvant.
- Trial name
- NCT05270265
- Testing
- Pvs25-IMX313/Matrix-M1
- Where
- United Kingdom
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Malaria
Plasmodium Vivax Efficacy Trial in Cruzeiro do Sul, Acre, Brazil
Background: The World Health Organization recommends that antimalarial treatment policies be evaluated every few years to check their efficacy. P.
- Trial name
- NCT02043652
- Testing
- Chloroquine, Primaquine
- Where
- Brazil
- Volunteers
- 119 people, healthy volunteers welcome
- Sponsor
- Centers for Disease Control and Prevention
P Vivax, Malaria, Vivax
Efficacy of 3 Regimens of Chloroquine and Primaquine for Treatment of P. Vivax Malaria, Cruzeiro do Sul, Acre, Brazil
We plan to assess the efficacy of 3 different regimens of chloroquine and primaquine for the treatment of P. vivax infections in Cruzeiro do Sul, Acre, Brazil.
- Trial name
- NCT03610399
- Testing
- Primaquine
- Where
- Brazil
- Volunteers
- 257 people
- Sponsor
- Centers for Disease Control and Prevention
Malaria, Vivax, G6PD Deficiency
Assessing a Risk Model for G6PD Deficiency
A clinical study designed to develop and inform an individual risk of hemolysis model based on individual red blood cell G6PD levels.
- Trial name
- NCT03337152
- Testing
- primaquine, chloroquine + primaquine
- Where
- Thailand
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- PATH
Malaria, Vivax
Safety, Immunogenicity and Efficacy of the Blood-stage Plasmodium Vivax Malaria Vaccine Candidate PvDBPII in Matrix M1
This is an Open label, first-in-human, Phase I/IIa, blood-stage P. vivax malaria vaccine trial to assess the safety, immunogenicity and efficacy of the blood-stage Plasmodium vivax malaria vaccine candidate PvDBPII in Matrix M1…
- Trial name
- NCT04201431
- Testing
- PvDBPII/Matrix-M1
- Where
- United Kingdom
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Malaria, Falciparum Malaria
TES of Artemether-lumefantrine for Pf and Chloroquine for Pv in the Philippines From 2013-2014
An antimalarial drug efficacy trial was conducted for artemether-lumefantrine (AL) and chloroquine (CQ) in the three (3) municipalities (Bataraza, Brookes and Rizal) of Palawan.
- Conditions
- Malaria, Falciparum Malaria, Vivax Malaria, Malaria Recrudescence
- Trial name
- TES (NCT04222088)
- Testing
- Arthemeter-lumefantrine, Chloroquine, Primaquine
- Volunteers
- 159 people
- Sponsor
- Research Institute for Tropical Medicine, Philippines
Malaria Falciparum, Malaria Vivax
A Study to Investigate the Safety, Tolerability and Pharmacokinetics of OZ439 in Healthy Male and Female Subjects
OZ439 is a synthetic trioxolane that has potential value as a peroxide antimalarial agent. This was a Phase I, single-centre, multi-component, double-blind, randomised, placebo-controlled study in healthy male and female…
- Conditions
- Malaria Falciparum, Malaria Vivax, Healthy Volunteers
- Trial name
- NCT00928083
- Testing
- OZ439 50mg API capsules, OZ439 200mg API capsules, OZ439 400mg aqueous dispersion
- Where
- United States
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Medicines for Malaria Venture
Malaria, Vivax
A Pharmacokinetics, Safety and Efficacy Study of Tafenoquine (TQ) in Pediatric Subjects With Plasmodium Vivax (P. Vivax) Malaria
This is a prospective, open-label, multicenter, non-comparative, single arm study of pediatric subjects with Plasmodium vivax (P. vivax) malaria, aged 6 months to <16 years of age. A total of 60 subjects will be enrolled.
- Trial name
- NCT02563496
- Testing
- Tafenoquine, Chloroquine
- Where
- 4 sites in Colombia, Vietnam
- Volunteers
- 60 people
- Sponsor
- GlaxoSmithKline
Malaria
Efficacy, Safety, Tolerability and Pharmacokinetics of KAF156 in Adult Patients With Acute, Uncomplicated Plasmodium Falciparum or Vivax Malaria Mono-infection
This study will assess efficacy, safety , tolerability and PK in uncomplicated adult malaria patients with P. vivax or P. falciparum infection after 3 day dosing with KAF156 at 400 mg/day (Part 1) and single dosing with KAF156 at…
- Trial name
- NCT01753323
- Testing
- KAF156
- Where
- 5 sites in Thailand, Vietnam
- Volunteers
- 43 people
- Sponsor
- Novartis Pharmaceuticals
Malaria, Vivax
VAC071: A Study to Assess Efficacy of the ChAd63/MVA PvDBP Vaccines
This is an open label, Phase IIa, controlled human malaria infection (CHMI) study aimed to assess whether the new vivax malaria vaccines ChAd63 PvDBP and MVA PvDBP can protect against malaria infection.
- Trial name
- NCT04009096
- Testing
- ChAd63 PvDBP and MVA PvDBP
- Where
- United Kingdom
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Malaria, Falciparum, Malaria, Vivax
Efficacy, Tolerability, PK of OZ439 in Adults With Acute, Uncomplicated P.Falciparum or Vivax Malaria Mono-infection
A Phase IIa Exploratory, Open label, Single Dose Regimen, Multiple Dose Testing Clinical Study to Assess the Preliminary Efficacy, Tolerability and Pharmacokinetics of OZ439 in adult patients with acute, uncomplicated Plasmodium…
- Trial name
- NCT01213966
- Testing
- OZ439
- Volunteers
- 82 people
- Sponsor
- Medicines for Malaria Venture
Malaria, Vivax
Study to Assess the Incidence of Hemolysis, Safety, and Efficacy of Tafenoquine (SB-252263, WR238605) Versus Primaquine in Subjects With Plasmodium Vivax Malaria
This is a prospective, double-blind, double-dummy, multicenter, comparative study. A total of 300 subjects will be randomized to treatment on Day 1, of which a minimum of 50 female subjects must be enrolled that display moderate…
- Trial name
- NCT02216123
- Testing
- Tafenoquine, Chloroquine, Primaquine
- Where
- 10 sites in Brazil, Colombia and 4 more
- Volunteers
- 251 people
- Sponsor
- GlaxoSmithKline
Malaria, Vivax
Ph 2B/3 Tafenoquine (TFQ) Study in Prevention of Vivax Relapse
The purpose of this two part study is to test the safety and efficacy of Tafenoquine (with Cholorquine) as a radical cure for Plasmodium vivax (P.vivax) malaria relative to the control Chloroquine.Part 1 aims to select an…
- Trial name
- NCT01376167
- Testing
- Chloroquine 600mg, Chloroquine 300mg, Tafenoquine 50mg
- Where
- 14 sites in Bangladesh, Brazil and 6 more
- Volunteers
- 851 people
- Sponsor
- GlaxoSmithKline
Malaria, Plasmodium Vivax
Study of VMP001 and AS01B (Adjuvant Formulation) in Healthy Malaria-Naïve Adults
This is a first-in-humans safety, immunogenicity and efficacy study with recombinant protein VMP001, a Plasmodium vivax circumsporozoite (CS) protein based vaccine.
- Trial name
- NCT01157897
- Testing
- VMP001, P. vivax sporozoite challenge
- Where
- United States
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
Malaria, Plasmodium Vivax
Study to Evaluate the Efficacy and Safety of Tafenoquine for the Treatment of Plasmodium Vivax in Adults
This Phase II study is designed to determine whether a single 600 mg dose or 400mg/day for 3 days of tafenoquine is efficacious, and well tolerated for clearing P.
- Trial name
- NCT01290601
- Testing
- Tafenoquine, Chloroquine + Primaquine
- Where
- Thailand
- Volunteers
- 70 people
- Sponsor
- U.S. Army Medical Research and Development Command
Malaria
Pyronaridine Artesunate (3:1) in Children and Adults With Acute Plasmodium Vivax Malaria
The purpose of this study is to compare the efficacy and safety of the fixed combination of pyronaridine artesunate (Pyramax®, PA) (180:60 mg) with that of standard chloroquine therapy in children and adults with acute…
- Trial name
- NCT00440999
- Testing
- Pyronaridine artesunate, Chloroquine
- Where
- 5 sites in Cambodia, India and 2 more
- Volunteers
- 456 people
- Sponsor
- Medicines for Malaria Venture
Malaria
A Study to Characterise the Antimalarial and Transmission Blocking Activity of a Single Dose of DSM265 or OZ439 in Healthy Subjects With Induced Blood Stage Plasmodium Falciparum or Plasmodium Vivax Infection
Part A -Cohort 1 DSM265 will be administered as a single dose (400 mg). For cohort 1 only, an additional single dose (400 mg) of DSM265 may be given if gametocytemia develops.
- Trial name
- DSMOZ-2 (NCT02573857)
- Testing
- DSM265, OZ439
- Where
- Australia
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Medicines for Malaria Venture
Malaria, Vivax
VAC069: A Study of Blood-stage Controlled Human P. Vivax Infection
This is a clinical study to assess the safety and feasibility of Plasmodium vivax (P. vivax) controlled blood-stage human malaria infection (CHMI), by inoculation using a newly created source of P. vivax malaria-infected blood.
- Trial name
- NCT03797989
- Testing
- P. vivax infected inoculum (parasitised red blood cells)
- Where
- United Kingdom
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Malaria, Vivax
Efficacy and Safety Study of Tafenoquine (TQ) Co-administered With Dihydroartemisinin-piperaquine (DHA-PQP) for the Radical Cure of Plasmodium Vivax (P. Vivax) Malaria
Tafenoquine (TQ) is an 8-aminoquinoline anti-malarial drug which is in development as a single-dose treatment for the radical cure of P.vivax malaria when given with standard doses of chloroquine.
- Trial name
- NCT02802501
- Testing
- Tafenoquine, Primaquine, Dihydroartemisinin-piperaquine (DHA-PQP)
- Where
- Indonesia
- Volunteers
- 150 people
- Sponsor
- GlaxoSmithKline